Published:
Category: Group updates
CCTG 2023-2024 New Investigator Cancer Trials Practicum
Applications are now open. This unique program and the first of its kind in Canada. It enables the best and brightest new Canadian oncology researchers to acquire training and experience in cancer clinical trial conduct. Read More

Published:
Category: Group updates
Frances Shepherd Award now accepting applications
CCTG is now accepting applications for the 2023 Frances Shepherd Award for any travel related to CCTG work (prior to travel and before the application deadline).
 
The Frances Shepherd Award is disbursed to one to two investigators or post-graduate trainees, traveling to present CCTG related work at major international meetings where the material has been accepted for presentation. Each award will be $1000.
Read More

Published:
Category: Group updates
Seeking CCTG Small Cell Lung Cancer (SCLC) Working Group Chair
The applicant should be a medical, radiation, surgical oncologist or pathologist, who has a research interest in SCLC, with leadership experience in clinical trials. The successful working group chair will work with the thoracic disease site leadership and executive to develop clinical trial proposals in SCLC, and be a champion of the working group to engage new and existing members to further its goals.
Read More

Published:
Category: Publications
Publications: MA9, MAC4-5, EN10-EN11, CRC6, general review
MA9 publication: Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 MAC4-5 : Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials EN10-EN11 : Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program CRC6: Physical Activity in Stage III Colon Cancer General Review : Reproductive Outcomes in Young Breast Cancer Survivors Treated (15-39) in Ontario, Canada Read More

Published:
Category: Publications
An understudied type of cancer receives new attention, with the potential to treat tumours that have spread to other parts of the body

Oral presentation at the ASCO Gastrointestinal Cancer Symposium 2023 of results for the Canadian Cancer Trials Group (CCTG) HE1 phase III study of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver metastases.

Read More

Published:
Category: Publications
INTEGRATE Oral presentation at ASCO GI 2023

The INTEGRATE IIa  (CCTG GA3) study, a phase III trial evaluated regorafenib for the treatment of patients with advanced gastro-oesophageal cancer (AGOC), has met its primary endpoint of a statistically significant improvement in overall survival of about 30%. The study evaluated the efficacy and safety of regorafenib in patients with AGOC, whose disease has progressed after a minimum of two lines of prior anti-cancer therapy for recurrent/metastatic disease. The safety and tolerability were generally consistent with the known profile of regorafenib.

Read More

Published:
Category: Publications
The ASCO Gastrointestinal Cancers Symposium was held last weekend January 19-21, 2023 in Moscone West, San Francisco, CA. CCTG support some great trial results and posters. Pictured is Dr Solar Vasconcelos who was honoured with a merit award for his poster at #GI23 on Predictive & prognostic features of metastatic colorectal cancer arising from the transverse colon: a pooled analysis of the CCTG CO17/CO20 trials with Dr Jonathan Loree and Senior Investigator Chis O'Callaghan Read More

Published:
Category: Trials
Permanent Trial Closures: HD8, PNC1, IND231, MA26
Permanent closure of the HD8 BEACOPP (4 cycles escalated + 4 cycles baseline) versus ABVD (8 cycles) in stage III & IV Hodgkin's lymphoma trial.
 

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating stage III or stage IV Hodgkin's lymphoma.

Read More